Research progress on the relationship between obesity and thyroid cancer and its molecular mechanism
Zhou Zheng1,2, Xu Shiying2,3, Wang Jiafeng2,3
1Bengbu Medical College Graduate School, Bengbu 233030, China; 2Department of Head and Neck Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China; 3Zhejiang Provincial Key Laboratory of Diagnosis and Treatment of Endocrine Gland Diseases, Hangzhou 310014, China
Abstract：Objective To summarize the latest advances in the study on the relationship between obesity and thyroid cancer and its molecular mechanism. Methods Chinese and English databases, such as CNKI, Wanfang, and PubMed, were searched by using Chinese and English keywords, such as "肥胖" "甲状腺癌" "促甲状腺激素" "脂肪因子" "胰岛素抵抗" "脂联素" and "obesity" "thyroid cancer" "thyroid stimulating hormone" "adipokines" "insulin resistance" "adiponectin", for 901 articles published before 2021 regarding the relationship between obesity and thyroid cancer and its molecular mechanism. The final 37 papers were summarized and analyzed by eliminating the papers that were not in accordance with the content, had unavailable full text, and were repeated. Results Epidemiological studies have confirmed that obesity is a risk factor for thyroid cancer. Recent studies have shown a correlation between obesity and the clinicopathologic features of thyroid cancer. The relationship between obesity and the prognosis of thyroid cancer is controversial, and the reasons may be related to the length of follow-up time and the prognosis of surgical intervention for thyroid cancer. The molecular mechanism of obesity and the occurrence and development of thyroid cancer remains controversial and needs to be further studied. Conclusions Obesity is an important risk factor for thyroid cancer and is associated with the adverse clinicopathological factors of thyroid cancer. However, the relationship between obesity and the prognosis of thyroid cancer and the specific molecular mechanisms of obesity and the incidence of thyroid cancer are still unclear, which need to be studied further.
周政, 许世莹, 王佳峰. 肥胖与甲状腺癌的关系及其分子机制的研究进展[J]. 中华解剖与临床杂志, 2022, 27(1): 60-64.
Zhou Zheng, Xu Shiying, Wang Jiafeng. Research progress on the relationship between obesity and thyroid cancer and its molecular mechanism. Chinese Journal of Anatomy and Clinics, 2022, 27(1): 60-64.
Deng Y, Li H, Wang M, et al.Global burden of thyroid cancer from 1990 to 2017[J]. JAMA Netw Open, 2020, 3(6): e208759. DOI: 10.1001/jamanetworkopen.2020.8759.
[2]
Barrea L, Gallo M, Ruggeri RM, et al.Nutritional status and follicular-derived thyroid cancer: an update[J]. Crit Rev Food Sci Nutr, 2021, 61(1): 25-59. DOI: 10.1080/10408398.2020.1714542.
[3]
Kitahara CM, Sosa JA.The changing incidence of thyroid cancer[J]. Nat Rev Endocrinol, 2016, 12(11): 646-653. DOI: 10.1038/nrendo.2016.110.
[4]
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026): 1377-1396. DOI: 10.1016/S0140-6736(16)30054-X.
[5]
Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies[J]. Thyroid, 2016, 26(2): 306-318. DOI: 10.1089/thy.2015.0319.
[6]
Shin HY, Jee YH, Cho ER.Body mass index and incidence of thyroid cancer in Korea: the Korean cancer prevention study-II[J]. J Cancer Res Clin Oncol, 2017,143(1):143-149. DOI: 10.1007/s00432-016-2261-x.
[7]
He Q, Sun H, Li F, et al.Obesity and risk of differentiated thyroid cancer: a large-scale case-control study[J]. Clin Endocrinol (Oxf), 2019, 91(6):869-878. DOI: 10.1111/cen.14091.
[8]
Bhaskaran K, Douglas I, Forbes H, et al.Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults[J]. Lancet, 2014, 384(9945): 755-765. DOI: 10.1016/S0140-6736(14)60892-8.
[9]
Kitahara CM, Pfeiffer RM, Sosa JA, et al.Impact of overweight and obesity on us papillary thyroid cancer incidence trends (1995-2015)[J]. J Natl Cancer Inst, 2020, 112(8): 810-817. DOI: 10.1093/jnci/djz202.
[10]
Kwon H, Chang Y, Cho A, et al.Metabolic Obesity phenotypes and thyroid cancer risk: a cohort study[J]. Thyroid, 2019, 29(3): 349-358. DOI: 10.1089/thy.2018. 0327.
[11]
Park JH, Choi M, Kim JH, et al.Metabolic syndrome and the risk of thyroid cancer: a nationwide population-based cohort study[J]. Thyroid, 2020, 30(10): 1496-1504. DOI: 10.1089/thy.2019.0699.
[12]
Lauby-Secretan B, Dossus L, Marant-Micallef C, et al.Obesity and cancer[J]. Bull Cancer, 2019, 106(7-8): 635-646. DOI: 10.1016/j.bulcan.2019.04.008.
[13]
Kim SH, Park HS, Kim KH, et al.Correlation between obesity and clinicopathological factors in patients with papillary thyroid cancer[J]. Surg Today, 2015, 45(6): 723-729. DOI: 10.1007/s00595-014-0984-3.
[14]
Kim SK, Woo JW, Park I, et al.Influence of body mass index and body surface area on the behavior of papillary thyroid carcinoma[J]. Thyroid, 2016, 26(5): 657-666. DOI: 10.1089/thy.2015.0632.
[15]
Zhao S, Jia X, Fan X, et al.Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: a retrospective case-control study[J]. Medicine (Baltimore), 2019, 98(50): e18213. DOI: 10.1097/MD.0000000000018213.
[16]
Wang H, Wang P, Wu Y, et al.Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1 579 cases: a retrospective study[J]. Peer J, 2020, 8: e9675. DOI: 10.7717/peerj.9675.
[17]
Li C, Zhou L, Dionigi G, et al.The association between tumor tissue calcification, obesity, and thyroid cancer invasiveness in a cohort study[J]. Endocr Pract, 2020, 26(8): 830-839. DOI: 10.4158/EP-2020-0057.
[18]
Trésallet C, Seman M, Tissier F, et al.The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices[J]. Surgery, 2014, 156(5): 1145-1152. DOI: 10.1016/j.surg.2014.04.020.
[19]
Yu ST, Chen W, Cai Q, et al.Pretreatment BMI is associated with aggressive clinicopathological features of papillary thyroid carcinoma: a multicenter study[J]. Int J Endocrinol, 2017, 2017: 5841942. DOI: 10.1155/2017/5841942.
[20]
Chung YS, Lee JH, Lee YD.Is body mass index relevant to prognosis of papillary thyroid carcinoma? A clinicopathological cohort study[J]. Surg Today, 2017, 47(4): 506-512. DOI: 10.1007/s00595-016-1417-2.
[21]
Feng JW, Yang XH, Wu BQ, et al.Influence of body mass index on the clinicopathologic features of papillary thyroid carcinoma[J]. Ann Otol Rhinol Laryngol, 2019, 128(7): 625-632. DOI: 10.1177/0003489419834314.
[22]
Kim J, Gosnell JE, Roman SA.Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1): 17-29. DOI: 10.1038/s41574-019-0263-x.
[23]
Marcello MA, Cunha LL, Batista FA, et al.Obesity and thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(5): T255-271. DOI: 10.1530/ERC-14-0070.
[24]
Xing M.Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3): 184-199. DOI: 10.1038/nrc3431.
[25]
Bétry C, Challan-Belval MA, Bernard A, et al.Increased TSH in obesity: evidence for a BMI-independent association with leptin[J]. Diabetes Metab, 2015, 41(3): 248-251. DOI: 10.1016/j.diabet.2014.11.009.
[26]
Du FM, Kuang HY, Duan BH, et al.Effects of thyroid hormone and depression on common components of central obesity[J]. J Int Med Res, 2019, 47(7): 3040-3049. DOI: 10.1177/0300060519851624.
[27]
Yin DT, He H, Yu K, et al.The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis[J]. Int J Surg, 2018, 57: 66-75. DOI: 10.1016/j.ijsu.2018.07.013.
[28]
Vella V, Malaguarnera R.The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12):3814. DOI: 10.3390/ijms19123814.
[29]
Zhou Y, Yang Y, Zhou T, et al.Adiponectin and thyroid cancer: insight into the association between adiponectin and obesity[J]. Aging Dis, 2021, 12(2): 597-613. DOI: 10.14336/AD.2020.0919.
[30]
Coperchini F, Pignatti P, Carbone A, et al.TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer[J]. Tumour Biol, 2016, 37(4): 5569-5575. DOI: 10.1007/s13277-015-4418-7.
[31]
Kobawala TP, Trivedi TI, Gajjar KK, et al.Significance of interleukin-6 in papillary thyroid carcinoma[J]. J Thyroid Res, 2016, 2016: 6178921. DOI: 10.1155/2016/6178921.
[32]
Dossus L, Franceschi S, Biessy C, et al.Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study[J]. Int J Cancer, 2018, 142(7): 1332-1342. DOI: 10.1002/ijc.31172.
[33]
Tumminia A, Vinciguerra F, Parisi M, et al.Adipose tissue, obesity and adiponectin: role in endocrine cancer risk[J]. Int J Mol Sci, 2019, 20(12): 2863. DOI: 10.3390/ijms20122863.
[34]
Kwon H, Park SE, Yun JS, et al.Serum Adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer[J]. Endocrinol Metab (Seoul), 2020, 35(2): 396-406. DOI: 10.3803/EnM.2020.35.2.396.
[35]
Fan YL, Li XQ.Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes[J]. Clin Endocrinol (Oxf), 2015, 83(2): 261-267. DOI: 10.1111/cen.12598.
[36]
Park JW, Han CR, Zhao L, et al.Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model[J]. Endocr Relat Cancer, 2016, 23(1): 53-63. DOI: 10.1530/ERC-15-0417.
[37]
Wu C, Wang L, Chen W, et al.Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer: a retrospective study[J]. Medicine (Baltimore), 2017, 96(9): e6202. DOI: 10.1097/MD. 0000000000006202.
2022, Vol. 27 
